Business
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory diseases.China innovation engine provides cost-efficient vehicle for discovery and early-stage development of targeted protein degraders and degrader-antibody conjugates. Strengthened leadership team in U.S., coupled with China operating presence to support future global growth. SAN DIEGO, May
About this update from Gyre Therapeutics, Inc.
[{"type":"image","alt":"Gyre Therapeutics Inc.","displaySize":"","headline":null,"caption":"Gyre Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/c821ee8b66ffe1346b42dcf8cb4fcc33"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZZ7gx8fH_Oooli7z1WaHxw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4/https://media.zenfs.com/en/globenewswire.com/c821ee8b66ffe1346b42dcf8cb4fcc33","width":300,"height":63}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory diseases.","length":215,"tagName":"p"}]},{"val":[{"type":"text","content":"China innovation engine provides cost-efficient vehicle for discovery and early-stage development of targeted protein degraders and degrader-antibody conjugates. ","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened leadership team in U.S., coupled with China operating presence to support future global growth.","length":108,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":484,"olType":false},{"type":"text","content":"SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, today announced the closing of its acquisition of Cullgen Inc. (Cullgen), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader (TPD) and degrader antibody conjugate (DAC) therapies, in an all-stock transaction valued at approximately $300 million.","length":611,"tagName":"p"},{"type":"text","content":"Following the closing of the acquisition, Cullgen became a wholly owned subsidiary of Gyre, and the former Chief Executive Officer of Cullgen, Dr. Ying Luo, was appointed President and Chief Executive Officer and as a member of the Gyre Board of Directors. Ping Zhang will continue at Gyre as Chairman of the Board of Directors. The new combined entity will continue to be listed on the Nasdaq Capital Market ...